Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTNS for Persistent OAB Post-BPH Surgery
NCT06558539Phase 3Not yet recruiting
- Sponsor
- Qingyuan Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Feb 2025
01
Overview
Phase 3, randomised, open-label trial (3 arms), sponsored by Qingyuan Pharmaceutical. Primary endpoint: Average Daily Urination Frequency Compared to Baseline at 12 weeks. Planned start Sep 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06558539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558539.